Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168007 | 0.89 | CES1 (0.55) | CES1CES2TSHRALDH1A1DAO | |
| Hydrochloric Acid SCHEMBL28496848 | 0.86 | CES1 (0.52) | CES1CES2TSHRALDH1A1DAO | |
| Hydrogen Sulfide SCHEMBL28111724 | 0.86 | CES1 (0.52) | CES1CES2TSHRALDH1A1DAO | |
| Water SCHEMBL27612226 | 0.86 | CES1 (0.52) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL8932412 | 0.81 | CES1 (0.43) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL5031044 | 0.80 | KMT2A (0.47) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL11742945 | 0.80 | CES1 (0.46) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL8494639 | 0.80 | CA2 (0.48) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL11621561 | 0.78 | HPGD (0.48) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL11623306 | 0.78 | CES1 (0.48) | CES1CES2TSHRALDH1A1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492220-B2 | Method for the preparation of oligonucleotides | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2025-12-09 | — | — | US | claimed |
| US-20230192751-A1 | METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) | 2023-06-22 | — | — | US | claimed |
| US-8304532-B2 | Method for preparing oligonucleotides | GIRINDUS AG (DE) | 2012-11-06 | — | — | US | claimed |
| EP-1525212-B1 | METHOD FOR PREPARING OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2012-09-12 | — | — | EP | claimed |
| US-20110224424-A1 | Method for preparing oligonucleotides | GIRINDUS AG (DE) | 2011-09-15 | — | — | US | claimed |
| US-20100069623-A1 | Method for preparing oligonucleotides | GIRINDUS AG (DE) | 2010-03-18 | — | — | US | claimed |
| US-20060089494-A1 | Method for preparing oligonucleotides | GIRINDUS AG (DE) | 2006-04-27 | — | — | US | claimed |
| EP-1525212-A1 | METHOD FOR PREPARING OLIGONUCLEOTIDES | Girindus AG (DE) | 2005-04-27 | — | — | EP | claimed |
| EP-0948512-B1 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2004-10-06 | — | — | EP | claimed |
| WO-2004013154-A1 | METHOD FOR PREPARING OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2004-02-12 | — | — | WO | claimed |
| EP-1386925-A1 | Method for preparing oligonucleotides | Girindus AG (DE) | 2004-02-04 | — | — | EP | claimed |
| US-20030114662-A1 | Method of synthesizing phosphorothioate oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | claimed |
| US-20020128466-A1 | Method of synthesizing phosphorothioate oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2002-09-12 | — | — | US | claimed |
| US-6403781-B2 | REACTING A PHOSPHORDIAMIDITE WITH A SUPPORT-BOUND SYNTHON TO FORM A SUPPORT BOUND PHOSPHORAMIDITE, PROTECTING TO FORM A SUPPORT BOUND PHOSHITE, SULFURIZING THE PHOSPHITE TO FORM A PROTECTED PHOSPHORTHIOATE AND DEPROTECTING | ISIS PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | claimed |
| EP-0948512-A4 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2001-10-24 | — | — | EP | claimed |
| US-20010003132-A1 | Method of synthesizing phosphorothioate oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2001-06-07 | — | — | US | claimed |
| US-6172217-B1 | SULFURIZATION OF PHOSPORDIAMIDITE; DEBLOCKING | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | claimed |
| EP-0948512-A1 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998029427-A1 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| US-12590115-B2 | Technologies useful for oligonucleotide preparation | WAVE LIFE SCIENCES LTD. (SG) | 2026-03-31 | — | — | US | disclosed |
| US-20260008806-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD (SG) | 2026-01-08 | — | — | US | disclosed |
| US-12492220-B2 | Method for the preparation of oligonucleotides | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2025-12-09 | — | — | US | disclosed |
| US-12435105-B2 | Technologies for oligonucleotide preparation | WAVE LIFE SCIENCES LTD. (SG) | 2025-10-07 | — | — | US | disclosed |
| US-20240327448-A1 | LITHIUM REAGENTS AND THEIR USES IN SOLID PHASE SYNTHESIS | OLIX US, INC. | 2024-10-03 | — | — | US | disclosed |
| WO-2024173777-A1 | LITHIUM REAGENTS AND THEIR USES IN SOLID PHASE SYNTHESIS | OLIX US, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240158432-A1 | COMPOSITIONS COMPRISING DICHLOROACETIC ACID, PROCESSES FOR PREPARING SAME AND USES THEREOF | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2024-05-16 | — | — | US | disclosed |
| US-11873318-B2 | Compositions comprising dichloroacetic acid, processes for preparing same and uses thereof | CHANGZHOU SYNTHEALL PHARMACEUTICALS CO., LTD. (CN) | 2024-01-16 | — | — | US | disclosed |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| US-20230192751-A1 | METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) | 2023-06-22 | — | — | US | disclosed |
| US-20230123981-A1 | 4'-O-METHYLENE PHOSPHONATE NUCLEIC ACIDS AND ANALOGUES THEREOF | NOVO NORDISK A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| EP-4153605-A1 | COMPOSITIONS COMPRISING DICHLOROACETIC ACID, PROCESSES FOR PREPARING SAME AND USES THEREOF | Changzhou Syntheall Pharmaceuticals Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-20230089442-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-23 | — | — | US | disclosed |
| US-11608355-B2 | Technologies for oligonucleotide preparation | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-21 | — | — | US | disclosed |
| CN-115836080-A | Composition comprising dichloroacetic acid, process for its preparation and its use | 常州合全药业有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20230002438-A1 | COMPOSITIONS COMPRISING DICHLOROACETIC ACID, PROCESSES FOR PREPARING SAME AND USES THEREOF | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| CN-115298192-A | 4' -O-methylene phosphonate nucleic acids and analogs thereof | 迪克纳制药公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-3941924-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | Wave Life Sciences Ltd. (SG) | 2022-01-26 | — | — | EP | disclosed |
| CN-113748116-A | Techniques useful for oligonucleotide preparation | 波涛生命科学有限公司 | 2021-12-03 | — | — | CN | disclosed |
| WO-2021233406-A1 | COMPOSITIONS COMPRISING DICHLOROACETIC ACID, PROCESSES FOR PREPARING SAME AND USES THEREOF | CHANGZHOU SYNTHEALL PHARMACEUTICALS CO., LTD. (CN) | 2021-11-25 | — | — | WO | disclosed |
| US-20210309690-A1 | OLIGONUCLEOTIDE SYNTHESIS | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2021-10-07 | — | — | US | disclosed |
| WO-2021146488-A1 | 4'-O-METHYLENE PHOSPHONATE NUCLEIC ACIDS AND ANALOGUES THEREOF | DICERNA PHARMACEUTICALS, INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20200392491-A1 | Method of Preparing Oligonucleotide Compounds | NOGRA PHARMA LIMITED (IE) | 2020-12-17 | — | — | US | disclosed |
| WO-2020191252-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | WO | disclosed |
| CN-111479818-A | Method and system for synthesizing oligonucleotides | 深圳华大生命科学研究院 | 2020-07-31 | — | — | CN | disclosed |
| EP-3684755-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | Wave Life Sciences Ltd. (SG) | 2020-07-29 | — | — | EP | disclosed |
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-07-23 | — | — | US | disclosed |
| EP-3658155-A1 | METHOD OF PREPARING OLIGONUCLEOTIDE COMPOUNDS | Celgene Corporation (US) | 2020-06-03 | — | — | EP | disclosed |
| CN-111148519-A | Method for preparing oligonucleotide compound | 细胞基因公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-111108096-A | Oligonucleotide preparation technology | 波涛生命科学有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-3491002-A2 | SYNTHESIS OF OLIGONUCLEOTIDES COMPRISING ACHIRAL 3'-S- OR 5'-S-PHOSPHOROTHIOLATE INTERNUCLEOSIDE LINKAGE | Roche Innovation Center Copenhagen A/S (DK) | 2019-06-05 | — | — | EP | disclosed |
| CN-109641932-A | Oligonucleotide synthesis comprising connector between achirality 3 '-S- or 5 '-S phosphorothioic acid ester nucleosides | 罗氏创新中心哥本哈根有限公司 | 2019-04-16 | — | — | CN | disclosed |
| WO-2019055951-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019023439-A1 | METHOD OF PREPARING OLIGONUCLEOTIDE COMPOUNDS | CELGENE CORPORATION (US) | 2019-01-31 | — | — | WO | disclosed |
| EP-2331558-B1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES INC (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9896472-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170130029-A1 | POLYSULFIDE ADDITIVE, METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN RUBBER MIXTURES | LANXESS DEUTSCHLAND GMBH (DE) | 2017-05-11 | — | — | US | disclosed |
| EP-2540734-B1 | Process and reagents for oligonucleotide synthesis and purification | ALNYLAM PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9273086-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-1028124-B2 | Improved deprotection method for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20160002282-A1 | Protected Monomer and Method of Final Deprotection for RNA Synthesis | AGILENT TECHNOLOGIES, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20150240053-A1 | POLYSULFIDE ADDITIVE, METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN RUBBER MIXTURES | LANXESS DEUTSCHLAND GMBH (DE) | 2015-08-27 | — | — | US | disclosed |
| CN-104661832-A | Polysulphide additive, method for production thereof, and use thereof in rubber mixtures | LANXESS DEUTSCHLAND GMBH | 2015-05-27 | — | — | CN | disclosed |
| US-20140179875-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | GIRINDUS AMERICA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-1023310-B2 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8552175-B2 | Sulfur transfer reagents for oligonucleotide synthesis | A.M. Chemicals, Inc. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8541599-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8431693-B2 | Process for desilylation of oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-1501851-B1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | NITTO DENKO AVECIA INC (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2013017469-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | GIRINDUS AMERICA, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-1789460-B1 | POLYMERIC BEADS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS INC (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-2540734-A2 | Process and reagents for oligonucleotide synthesis and purification | Alnylam Pharmaceuticals, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-8304532-B2 | Method for preparing oligonucleotides | GIRINDUS AG (DE) | 2012-11-06 | — | — | US | disclosed |
| EP-1525212-B1 | METHOD FOR PREPARING OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8193337-B2 | Oxidation process | AVECIA BIOTECHNOLOGY, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| WO-2012059510-A1 | BACK PRESSURE CONTROL DURING SOLID-PHASE SYNTHESIS ON POLYMERIC SUPPORTS | GIRINDUS AMERICA, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-8153725-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120071640-A1 | Sulfurizing reagents and their use for oligonucleotides synthesis | GIRINDUS AMERICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093397-B2 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| CN-102307889-A | Sulfurizing reagents and their use for oligonucleotides synthesis | GIRINDUS AMERICA INC | 2012-01-04 | — | — | CN | disclosed |
| US-8063198-B2 | Processes and reagents for desilylation of oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8058448-B2 | Processes and reagents for sulfurization of oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2382227-A1 | SULFURIZING REAGENTS AND THEIR USE FOR OLIGONUCLEOTIDES SYNTHESIS | Girindus America, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| CN-101076546-B | Polymeric beads for oligomer synthesis | ISIS PHARMACEUTICALS INC | 2011-10-26 | — | — | CN | disclosed |
| US-20110224424-A1 | Method for preparing oligonucleotides | GIRINDUS AG (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20110196145-A1 | PROCESS FOR DESILYLATION OF OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110160082-A1 | Mobility-Modified Nucleobase Polymers and Methods of Using Same | Life Technologies Corporation (US) | 2011-06-30 | — | — | US | disclosed |
| EP-2331558-A2 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | Agilent Technologies, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110137021-A1 | SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | A.M. Chemicals, Inc. | 2011-06-09 | — | — | US | disclosed |
| US-7897338-B2 | Mobility-modified nucleobase polymers and methods of using same | APPLIED BIOSYSTEMS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1575975-B1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA BIOTECHNOLOGY INC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7759480-B2 | Chloral-free DCA in oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| WO-2010072831-A1 | SULFURIZING REAGENTS AND THEIR USE FOR OLIGONUCLEOTIDES SYNTHESIS | GIRINDUS AMERICA, INC (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100137572-A1 | OXIDATION PROCESS | NITTO DENKO AVECIA, INC. | 2010-06-03 | — | — | US | disclosed |
| US-7723511-B2 | Synthesis of sulfurized oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723528-B2 | Sulfur transfer reagents for oligonucleotide synthesis | AM CHEMICALS LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7718810-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7700706-B2 | Polymeric beads for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100076183-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2010-03-25 | — | — | US | disclosed |
| WO-2010034024-A2 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069623-A1 | Method for preparing oligonucleotides | GIRINDUS AG (DE) | 2010-03-18 | — | — | US | disclosed |
| US-7635772-B2 | Process for the preparation of oligonucleotides | AVECIA BIOTECHNOLOGY INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090306358-A1 | SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | AM CHEMICALS LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090286085-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| EP-1379698-B1 | MOBILITY-MODIFIED NUCLEOBASE POLYMERS AND METHODS OF USING SAME | APPLIED BIOSYSTEMS LLC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7576119-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090187027-A1 | PROCESSES AND REAGENTS FOR SULFURIZATION OF OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090085006-A1 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7511125-B2 | Pyrimidine derivatives for labeled binding partners | CARLSBAD (US) | 2009-03-31 | — | — | US | disclosed |
| US-7501505-B2 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| WO-2009007736-A1 | OXIDATION PROCESS | AVECIA BIOTECHNOLOGY INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-7476709-B2 | Process for preparing oligonucleotides | AVECIA BIOTECHNOLOGY INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20090005549-A1 | Processes and Reagents for Desilylation of Oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| EP-1212339-B1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080293929-A1 | SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| CN-100430411-C | Activators for oligonucleotide synthesis | AVECIA LTD (US) | 2008-11-05 | — | — | CN | disclosed |
| US-7446193-B2 | Methods for detection of chloral hydrate in dichloroacetic acid | ISIS PHARMACEUTICALS, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7427675-B2 | Compounds and methods for the characterization of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7378516-B2 | Synthesis of sulfurized oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20080119645-A1 | Immobilization; solid phase synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| CN-100384864-C | Process for the preparation of oligonucleotides | AVECIA LTD (US) | 2008-04-30 | — | — | CN | disclosed |
| US-20080097028-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | LSIS PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-7348391-B2 | Polymeric beads for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| CN-101076546-A | Polymeric beads for oligomer synthesis | ISIS PHARMACEUTICALS INC (US) | 2007-11-21 | — | — | CN | disclosed |
| US-20070265435-A1 | PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS | RAVIKUMAR VASULINGA T | 2007-11-15 | — | — | US | disclosed |
| EP-1028124-B1 | Improved deprotection method for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7276599-B2 | Oligonucleotide synthesis with alternative solvents | ISIS PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7273933-B1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070196847-A1 | METHODS FOR DETECTION OF CHLORAL HYDRATE IN DICHLOROACETIC ACID | ISIS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| EP-1490515-A4 | CHLORAL-FREE DCA IN OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-7227016-B2 | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7227015-B2 | Synthesis of sulfurized oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20070123703-A1 | CHLORAL-FREE DCA IN OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| EP-1789460-A2 | POLYMERIC BEADS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1379698-A4 | MOBILITY-MODIFIED NUCLEOBASE POLYMERS AND METHODS OF USING SAME | APPLERA CORP (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7199236-B2 | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7186822-B2 | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7173123-B2 | Methods for detection of chloral hydrate in dichloroacetic acid | ISIS PHARMACEUTICALS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070026434-A1 | Mobility-Modified Nucleobase Polymers and Methods of Using Same | APPLERA CORPORATION (US) | 2007-02-01 | — | — | US | disclosed |
| US-7169916-B2 | Chloral-free DCA in oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-RE39464-E1 | Oligonucleolotides having site specific chiral phosphorothioate internucleoside linkages | ISIS PHARMACEUTICALS INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20070004911-A1 | Silylated oligonucleotide compounds | AVECIA LIMITED (GB) | 2007-01-04 | — | — | US | disclosed |
| EP-1737878-A2 | PROCESS AND REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION | Alnylam Pharmaceuticals Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1356115-B1 | METHODS FOR DETECTION OF CHLORAL HYDRATE IN DICHLOROACETIC ACID | ISIS PHARMACEUTICALS INC (US) | 2006-11-29 | — | — | EP | disclosed |
| US-RE39324-E1 | Pyrimidine derivatives and oligonucleotides containing same | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060149052-A1 | Process for the preparation of oligonucleotides | AVECIA LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| US-7057027-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1660512-A2 | OLIGONUCLEOTIDE SYNTHESIS WITH ALTERNATIVE SOLVENTS | ISIS PHARMACEUTICALS, INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-0904275-B1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | UNIV MCGILL (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-7041816-B2 | solid phase deprotection of cyanoethyl groups on the phosphorothioate backbone of an oligonucleotide with an amine deprotecting agent (triethylamine); cleaving the oligonucleotide from the support; minimal acrylonitrile nucleobase adduct formation; by-product inhibition | ISIS PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20060089494-A1 | Method for preparing oligonucleotides | GIRINDUS AG (DE) | 2006-04-27 | — | — | US | disclosed |
| WO-2006029023-A2 | POLYMERIC BEADS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| CN-1747963-A | Process for preparing oligonucleotides | AVECIA LTD (GB) | 2006-03-15 | — | — | CN | disclosed |
| US-20060051800-A1 | Polymeric beads for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| US-20060041114-A1 | Activators for oligonucleotide synthesis | NITTO DENKO AVECIA, INC. | 2006-02-23 | — | — | US | disclosed |
| US-20060040308-A1 | Compounds and methods for the characterization of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | US | disclosed |
| US-7002006-B2 | Protection of nucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20060036028-A1 | Process for preparing oligonucleotides | NITTO DENKO AVECIA, INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1404696-B1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1097162-B1 | OLIGONUCLEOTIDES HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20060003952-A1 | Oligomeric compounds having modified phosphate groups | ISIS PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| EP-1608669-A1 | SILYLATED OLIGONUCLEOTIDE COMPOUNDS | Avecia Limited (GB) | 2005-12-28 | — | — | EP | disclosed |
| US-20050267300-A1 | Processes and reagents for oligonucleotide synthesis and purification | ALNYLAM PHARMACEUTICALS | 2005-12-01 | — | — | US | disclosed |
| US-6967079-B2 | Pyrimidine derivatives for labeled binding partners | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| WO-2005108411-A2 | SUBSTITUTED PIXYL PROTECTING GROUPS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-6962783-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| WO-2005097817-A2 | PROCESS AND REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-6951931-B2 | Pyrimidine derivatives for labeled binding partners | ISIS PHARMACEUTICALS, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050208588-A1 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| EP-1575975-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | Avecia Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| US-20050182251-A1 | Process for the synthesis of oligomeric compounds | IONIS PHARMACEUTICALS, INC. | 2005-08-18 | — | — | US | disclosed |
| CN-1649889-A | Process for preparing oligonucleotides | AVECIA LTD (GB) | 2005-08-03 | — | — | CN | disclosed |
| US-20050165226-A1 | Synthesis of sulfurized oligonucleotides | ISIS PHARMACEUTICALS INC. | 2005-07-28 | — | — | US | disclosed |
| US-20050137390-A1 | Process for the synthesis of oligomeric compounds | IONIS PHARMACEUTICALS, INC. | 2005-06-23 | — | — | US | disclosed |
| US-20050137391-A1 | Process for the synthesis of oligomeric compounds | IONIS PHARMACEUTICALS, INC. | 2005-06-23 | — | — | US | disclosed |
| US-20050113569-A1 | Methods for detection of chloral hydrate in dichloroacetic acid | ISIS PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| EP-1525212-A1 | METHOD FOR PREPARING OLIGONUCLEOTIDES | Girindus AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050075490-A1 | Chloral-free DCA in oligonucleotide synthesis | IONIS PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6875593-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-6870039-B2 | Synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| WO-2005020885-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-6861518-B2 | Hybrid oligonucleotide | MCGILL UNIVERSITY (CA) | 2005-03-01 | — | — | US | disclosed |
| US-20050042644-A1 | Mobility-modified nucleobase polymers and methods of using same | APPLERA CORPORATION (US) | 2005-02-24 | — | — | US | disclosed |
| EP-1317466-B1 | SYNTHONS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC (US) | 2005-02-23 | — | — | EP | disclosed |
| US-6858722-B2 | Oligomer phosphoramidite compositions and processes for synthesizing the same | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-6858715-B2 | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050026192-A1 | Oligonucleotide synthesis with alternative solvents | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| EP-1501851-A1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | Avecia Limited (GB) | 2005-02-02 | — | — | EP | disclosed |
| US-20050020826-A1 | Pyrimidine derivatives for labeled binding partners | LIN KUEI-YING (US) | 2005-01-27 | — | — | US | disclosed |
| US-6846922-B1 | Reacting phosphoramidite with hydroxyl group of nucleoside or oligonucleotide linked to solid support in presence of activating reagent comprising at least one pyridinium salt and at least one substituted imidazole | ISIS PHARMACEUTICALS, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | FROEHLER BRIAN (US) | 2004-12-30 | — | — | US | disclosed |
| WO-2004113553-A2 | METHOD OF PRODUCING PURE AMIDITES AND OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-1490515-A1 | CHLORAL-FREE DCA IN OLIGONUCLEOTIDE SYNTHESIS | ISIS Pharmaceuticals, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004108081-A2 | OLIGONUCLEOTIDE SYNTHESIS WITH ALTERNATIVE SOLVENTS | ISIS PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-1023310-B1 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1027364-B1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | disclosed |
| US-6825338-B2 | SELECTIVE FUNCTIONALIZATION OF OLIGONUCLEOTIDES WITH CONJUGATE GROUPS WITHOUT THE NEED FOR POST-SYNTHETIC LABELING; SOLID PHASE SYNTHESIS; DEBLOCKING AN ACID LABILE HYDROXYL GROUP AND REACTING WITH A PHOSPHORAMIDITE | ISIS PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| CN-1549820-A | Activators for oligonucleotide synthesis | ƽ | 2004-11-24 | — | — | CN | disclosed |
| US-20040220395-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040219577-A1 | Process for the synthesis of oligomeric compounds | IONIS PHARMACEUTICALS, INC. | 2004-11-04 | — | — | US | disclosed |
| US-6809195-B1 | COMPRISES A MODIFIED PHOSPHORAMIDITE PROTOCOL IN WHICH OXIDATION AND CAPPING STEPS ARE COMBINED INTO A SINGLE STEP; INCREASED EFFICIENCY; SOLID PHASE SYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2004-10-26 | — | — | US | disclosed |
| WO-2004085454-A1 | SILYLATED OLIGONUCLEOTIDE COMPOUNDS | AVECIA LIMITED (GB) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198972-A1 | Processes for the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2004-10-07 | — | — | US | disclosed |
| EP-0948512-B1 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-6800743-B2 | FOR USE AS LABELS IN DIAGNOSTIC ASSAYS AND IN ENHANCING BINDING TO COMPLEMENTARY BASES | ISIS PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | disclosed |
| US-20040185491-A1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004072234-A2 | PROTECTION OF NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-6780989-B2 | HYBRID OLIGONUCLEOTIDE | ISIS PHARMACEUTICALS, INC. | 2004-08-24 | — | — | US | disclosed |
| US-20040158055-A1 | Protection of nucleosides | IONIS PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040152905-A1 | Universal building blocks and support media for synthesis of oligonucleotides and their analogs | ISIS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| EP-0986571-B1 | NOVEL SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6762281-B2 | GENERATING PREFERENTIAL OLIGOMERS; GENERATE OLIGOMER, DEPROTECT, EXPOSE TO PHOSPHOROUS, OXIDIZE, EXPOSE TO SULFUR, CLEAVE, RECOVER PRODUCT | ISIS PHARMACEUTICALS, INC. | 2004-07-13 | — | — | US | disclosed |
| WO-2004055036-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2004-07-01 | — | — | WO | disclosed |
| EP-1356115-A4 | METHODS FOR DETECTION OF CHLORAL HYDRATE IN DICHLOROACETIC ACID | ISIS PHARMACEUTICALS INC (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1119578-B1 | IMPROVED PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS INC (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6743905-B2 | BIOPOLYMER FOR USE IN THE DETECTION OF PREERENTIAL SEQUENCES IN SAMPLE | APPLERA CORPORATION | 2004-06-01 | — | — | US | disclosed |
| EP-1084134-A4 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS INC (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040097722-A9 | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY | 2004-05-20 | — | — | US | disclosed |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | ISIS PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| CN-1489633-A | Method for detecting chloral hydrate in dichloroacetic acid | ISISҩ�﹫˾ | 2004-04-14 | — | — | CN | disclosed |
| EP-1404696-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | Avecia Biotechnology, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040063925-A1 | Synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2004013154-A1 | METHOD FOR PREPARING OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004011474-A1 | UNIVERSAL SUPPORT MEDIA FOR SYNTHESIS OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1386925-A1 | Method for preparing oligonucleotides | Girindus AG (DE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1379541-A1 | LABELED OLIGONUCLEOTIDES, METHODS FOR MAKING SAME, AND COMPOUNDS USEFUL THEREFOR | ISIS Pharmaceuticals, Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1379698-A1 | MOBILITY-MODIFIED NUCLEOBASE POLYMERS AND METHODS OF USING SAME | Applera Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6677471-B2 | USED FOR PREPARATION OF OLIGOMERIC COMPOUNDS HAVING PHOSPHITE, PHOSPHODIESTER, PHOSPHOROTHIOATE, PHOSPHORODITHIOATE OR OTHER LINKAGES | ISIS PHARMACEUTICALS, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030229218-A1 | Synthons for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030229220-A1 | Oligomer phosphoramidite compositions and processes for synthesizing the same | RAVIKUMAR VASULINGA T (US) | 2003-12-11 | — | — | US | disclosed |
| US-20030229219-A1 | Preparation of phosphorothioate oligomers | ISIS PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-6653468-B1 | Bicyclic heptane derivatives linked to controlled pore glass or copolymers of polystyrene; can be cleaved and used for subsequent reactions | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| US-6649750-B1 | Nucleoside linked to a support through heterocyclic base and amide bond; deblocking/deprotecting; capping/oxidizing; purity; reduced levels of byproducts containing abasic sites | ISIS PHARMACEUTICALS, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030212267-A1 | Synthesis of sulfurized oligonucleotides | IONIS PHARMACEUTICALS, INC. | 2003-11-13 | — | — | US | disclosed |
| US-6645716-B2 | Detecting nuclear magnetic resonance spectrum of chloral hydrate in sample; obtain sample of dichloroacetic acid, monitor resonance spectrum for presence of chloral hydrate | ISIS PHARMACEUTICALS, INC. | 2003-11-11 | — | — | US | disclosed |
| US-6646114-B2 | Especially phosphorothioate oligonucleotides, and to intermediates used in that process; solution phase synthesis having improved efficiencies and enhanced convenience and cost | ISIS PHARMACEUTICALS, INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030208061-A1 | Labeled oligonucleotides, methods for making same, and compounds useful therefor | ISIS PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003091267-A1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | MATTEUCCI MARK D (US) | 2003-11-06 | — | — | US | disclosed |
| US-6642373-B2 | Phosphitylating using pyridinium salt activators; forming phosphorate or phosphorothioate intersugar linkages | ISIS PHARMACEUTICALS, INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1356115-A1 | METHODS FOR DETECTION OF CHLORAL HYDRATE IN DICHLOROACETIC ACID | ISIS PHARMACEUTICALS, INC. (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2003085136-A1 | CHLORAL-FREE DCA IN OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| US-20030191304-A1 | Activators for oligonucleotide synthesis | IONIS PHARMACEUTICALS, INC. | 2003-10-09 | — | — | US | disclosed |
| US-20030190626-A1 | Phosphorothioate monoester modified oligomers | ISIS PHARMACEUTICALS, INC. | 2003-10-09 | — | — | US | disclosed |
| US-20030176677-A1 | Pyrimidine derivatives for labeled binding partners | IONIS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030170680-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | FROEHLER BRIAN (US) | 2003-09-11 | — | — | US | disclosed |
| US-6617437-B1 | Modified oligonucleotide of given formula; useful in diagnostics and therapeutics | ISIS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-6610842-B1 | Removing hydroxyl protecting group from compound of given formula and treating with another compound; wide range of diagnostic and therapeutic uses | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6610837-B1 | Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030153743-A1 | Processes for the synthesis of oligomeric compounds | MANOHARAN MUTHIAH (US) | 2003-08-14 | — | — | US | disclosed |
| US-20030149260-A1 | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-6596857-B1 | Oligomer for use as tool in human diagnostics and therapeutics | MCGILL UNIVERSITY (CA) | 2003-07-22 | — | — | US | disclosed |
| EP-1066308-A4 | IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030114662-A1 | Method of synthesizing phosphorothioate oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030114660-A1 | Preparation of phosphorothioate oligomers | JUST GEORGE (CA) | 2003-06-19 | — | — | US | disclosed |
| EP-1317466-A2 | SYNTHONS FOR OLIGONUCLEOTIDE SYNTHESIS | Avecia Biotechnology, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2003045969-A1 | COUPLING REAGENT FOR H-PHOSPHONATE CHEMISTRY | AVECIA BIOTECHNOLOGY INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030096980-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| EP-1311526-A1 | PROCESSES FOR THE PREPARATION OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030088088-A1 | Process for the synthesis of oligomeric compounds | IONIS PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| EP-0719272-B1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-6559279-B1 | Generation of peptide linked oligomers; generate solid support, expose to deprotecting agent, incubate with nucleoside, cap, cleave and recover peptide derivative | ISIS PHARMACEUTICALS, INC. | 2003-05-06 | — | — | US | disclosed |
| US-20030072712-A1 | Pyrimidine derivatives for labeled binding partners | LIN KUEI-YING (US) | 2003-04-17 | — | — | US | disclosed |
| US-20030069412-A1 | Synthesis of oligonucleotides | RAVIKUMAR VASULINGA (US) | 2003-04-10 | — | — | US | disclosed |
| EP-1246833-A4 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6531590-B1 | Having bioreversible phosphate blocking groups, using a phosphoramite reactant carrying the phosphate blocking group; designed for cleavage by carboxyesterases to yield unprotected oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20030045698-A1 | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| US-6521775-B2 | Genetically engineered oligonucleotides for use as diagnostic and therapeutic tools in gene therapy | ISIS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| EP-1244682-A4 | PROCESS FOR THE PREPARATION OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2003-02-05 | — | — | EP | disclosed |
| WO-2003004512-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC. (US) | 2003-01-16 | — | — | WO | disclosed |
| US-6500944-B2 | FOR SOLID PHASE BIOSYNTHESIS | AVECIA BIOTECHNOLOGY, INC. | 2002-12-31 | — | — | US | disclosed |
| US-20020182602-A1 | Mobility-modified nucleobase polymers and methods of using same | APPLIED BIOSYSTEMS, INC. | 2002-12-05 | — | — | US | disclosed |
| US-6486312-B2 | LIQUID PHASE BIOSYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2002-11-26 | — | — | US | disclosed |
| EP-1256589-A2 | Oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6476216-B1 | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 2002-11-05 | — | — | US | disclosed |
| US-20020156235-A1 | Process for preparing peptide derivatized oligomeric compounds | IONIS PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2002083954-A1 | MOBILITY-MODIFIED NUCLEOBASE POLYMERS AND METHODS OF USING SAME | APPLERA CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-0637965-B1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | disclosed |
| US-6465628-B1 | METHOD OF SYNTHESIS WITH DEPROTECTION OF OLIGOMERS | ISIS PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020147331-A1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002079216-A1 | LABELED OLIGONUCLEOTIDES, METHODS FOR MAKING SAME, AND COMPOUNDS USEFUL THEREFOR | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-1246833-A1 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6462184-B2 | PROVIDING A PURINE OR PYRIMIDINE BASE CONTAINING NUCLEOSIDE WITH ACID LABILE HYDROXYL PROTECTING GROUP AND A BASE LABILE HYDROXY PROTECTING GROUP SUBSTITUTIONS, DEBLOCKING HYDROXY GROUP, TREATING WITH PHOSPHONATE COMPOUND, CONDENSING AGENT | ISIS PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1244682-A1 | PROCESS FOR THE PREPARATION OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1175432-A4 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHOSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS INC (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1212339-A4 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20020128466-A1 | Method of synthesizing phosphorothioate oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2002-09-12 | — | — | US | disclosed |
| US-20020119483-A1 | Methods for detection of chloral hydrate in dichloroacetic acid | IONIS PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| EP-1159282-A4 | COMPOUNDS, PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MIXED BACKBONE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6440943-B1 | MIMIC AND/OR MODULATE THE ACTIVITY OF WILD-TYPE NUCLEIC ACIDS; THE 5' AND THE 3'-TERMINAL INTERNUCLEOSIDE LINKAGES ARE CHIRALLY SP AND INTERNAL INTERNUCLEOSIDE LINKAGES ARE CHIRALLY RP; RESISTANT TO NUCLEASE DEGRADATION; PSORIASIS | ISIS PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| WO-2002062811-A2 | IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002061138-A1 | METHODS FOR DETECTION OF CHLORAL HYDRATE IN DICHLOROACETIC ACID | ISIS PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-6414127-B1 | INCREASED AFFINITY TO COMPLEMENTARY OLIGONUCLEOTIDES; DNA SEQUENCING; MEDICAL DIAGNOSIS; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1112279-A4 | METHODS FOR THE PREPARATION OF CONJUGATED OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1212339-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6403781-B2 | REACTING A PHOSPHORDIAMIDITE WITH A SUPPORT-BOUND SYNTHON TO FORM A SUPPORT BOUND PHOSPHORAMIDITE, PROTECTING TO FORM A SUPPORT BOUND PHOSHITE, SULFURIZING THE PHOSPHITE TO FORM A PROTECTED PHOSPHORTHIOATE AND DEPROTECTING | ISIS PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-6399756-B1 | OLIGONUCLEOTIDE | ISIS PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-20020055623-A1 | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS. INC. | 2002-05-09 | — | — | US | disclosed |
| US-6384209-B1 | HIGHLY EFFIENT PROCESS BY CONTACTING OLIGONUCLEOTIDE HAVING INTERNUCLEOSIDE LINKAGE OF A PHOSPHOROUS III ATOM WITH A REAGENT OF DEFINED STRUCTURE; REAGENTS ARE INEXPENSIVE TO MAKE AND STABLE IN STORAGE | AVECIA BIOTECHNOLOGY, INC. (GB) | 2002-05-07 | — | — | US | disclosed |
| US-6380368-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1119578-A4 | IMPROVED PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS INC (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2002020543-A2 | SYNTHONS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002020544-A1 | PROCESS FOR PREPARING PEPTIDE DERIVATIZED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1097162-A4 | OLIGONUCLEOTIDES HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2002014340-A1 | PROCESSES FOR THE PREPARATION OF OLIGONUCLEOTIDES_______________ | ISIS PHARMACEUTICALS, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| EP-1175432-A1 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHUSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2002-01-30 | — | — | EP | disclosed |
| US-20020010326-A1 | NOVEL SULFURIZING REAGENT 3-PHENYL-1,2,4-DITHIAZOLINE-5-ONE | NITTO DENKO AVECIA, INC. | 2002-01-24 | — | — | US | disclosed |
| US-6335437-B1 | REACTING NUCLEOSIDE OR OLIGONUCLEOTIDE WITH ELECTROPHILIC HALOACETYL LINKER | ISIS PHARMACEUTICALS, INC. | 2002-01-01 | — | — | US | disclosed |
| EP-1159282-A1 | COMPOUNDS, PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MIXED BACKBONE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6326478-B1 | OLIGONUCLEOTIDES AND MEDICAL DIAGNOSIS, METABOLISM | ISIS PHARMACEUTICALS, INC. | 2001-12-04 | — | — | US | disclosed |
| EP-0948512-A4 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6294664-B1 | PREPARING OLIGONUCLEOTIDE BLOCKS HAVING COMMON SUBSEQUENCES, PHOSPITYLATING, AND PERFORMING SOLID PHASE SYNTHESIS (SPS) TO FORM TARGET OLIGONUCLEOTIDES WHEREIN THE SYNTHONS USED IN SPS COMPRISE PHOSPHITYLATED OLIGONUCLEOTIDE BLOCKS | ISIS PHARMACEUTICALS, INC. | 2001-09-25 | — | — | US | disclosed |
| US-20010018510-A1 | Synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2001-08-30 | — | — | US | disclosed |
| US-20010016652-A1 | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2001-08-23 | — | — | US | disclosed |
| US-6274725-B1 | PROVIDING COMPOUND HAVING A HYDROXYL GROUP; REACTING WITH PHOSPHITYLATING REAGENT IN THE PRESENCE OF A PYRIDINUM SALT IN A SOLVENT UNDER CONDITIONS OF TIME, TEMPERATURE AND PRESSURE TO YIELD PHOSPHITYLATED COMPOUND | ISIS PHARMACEUTICALS, INC. | 2001-08-14 | — | — | US | disclosed |
| EP-1119578-A1 | IMPROVED PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2001-08-01 | — | — | EP | disclosed |
| WO-2001051502-A1 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001049701-A1 | PROCESS FOR THE PREPARATION OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
| EP-1112279-A1 | METHODS FOR THE PREPARATION OF CONJUGATED OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-04 | — | — | EP | disclosed |
| US-20010003132-A1 | Method of synthesizing phosphorothioate oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2001-06-07 | — | — | US | disclosed |
| US-6242591-B1 | Synthesis of sulfurized 2'-substituted oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2001-06-05 | — | — | US | disclosed |
| EP-1023310-A4 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1097162-A2 | OLIGONUCLEOTIDES HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6211350-B1 | REACTING SYNTHON WITH TWO NUCLEOSIDE UNITS AND WITH SYNTHON HAVING ONE NUCLEOSIDE UNIT TO OBTAIN OLIGONUCLEOTIDE CONTAINING PHOSPHOROTHIOATE GROUPS | ISIS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6207819-B1 | SYNTHESIZING OLIGONUCLEOTIDE BY DEBLOCKING AND COUPLING NUCLEOTIDES TOGETHER, THEN TREATING WITH OXIDIZING SOLUTION TO CONVERT H-PHOSPHONATE LINKAGES TO PHOSPHODIESTER, PHOSPHOROTHIOATE, PHOSPHORAMIDATE OR BORANOPHOSPHATE | ISIS PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| EP-1084134-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-2001014400-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
| EP-1066308-A1 | IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-10 | — | — | EP | disclosed |
| US-6172217-B1 | SULFURIZATION OF PHOSPORDIAMIDITE; DEBLOCKING | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | disclosed |
| US-6169177-B1 | EFFICIENT REMOVAL OF ALLYL PROTECTING GROUPS DURING OLIGONUCLEOTIDE SYNTHESIS BY TREATING WITH SOLUTION OF CONCENTRATED AMMONIUM HYDROXIDE CONTAINING A MERCAPTO COMPOUND | ISIS PHARMACEUTICALS, INC. | 2001-01-02 | — | — | US | disclosed |
| US-6160152-A | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-6160109-A | Preparation of phosphorothioate and boranophosphate oligomers | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000068241-A1 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHUSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| US-6147200-A | NUCLEOSIDES FOR SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES HAVING INCREASED NUCLEASE RESISTANCE AND BETTER BINDING AFFINITY; DIAGNOSIS; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6124450-A | Processes and intermediates for phosphorous-containing covalent linkages | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-26 | — | — | US | disclosed |
| WO-2000055179-A1 | NOVEL PHOSPHATE AND THIOPHOSPHATE PROTECTING GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| US-6121437-A | SYNTHESIS OF OLIGONUCLEOTIDES USING OLIGONUCLEOTIDES OR NUCLEOTIDES WITH PROTECTED INTERNUCLEOSIDIC PHOSPHORUS FUNCTIONALITIES WHICH CAN BE REMOVED UNDER MILD CONDITIONS AND PRODUCE NONTOXIC BY-PRODUCTS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-6114519-A | PHOSPHITYLATION; OXIDATION ACYL DISULFIDE | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| WO-2000047593-A1 | COMPOUNDS, PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MIXED BACKBONE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| EP-1027364-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-16 | — | — | EP | disclosed |
| EP-1028124-A2 | Improved process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-16 | — | — | EP | disclosed |
| EP-1023310-A1 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-02 | — | — | EP | disclosed |
| US-6096881-A | Sulfur transfer reagents for oligonucleotide synthesis | HYBRIDON, INC. (US) | 2000-08-01 | — | — | US | disclosed |
| US-6084082-A | SOLID PHASE SYNTHESIS BY ATTACHING BETA-LACTAM HAVING NUCLEOBASE TO SOLID SUPPORT, DEPROTECTING HYDROXY GROUP, REACTING FREE HYDROXYL GROUP WITH BETA-LACTAMTIDE HAVING ACTIVATED PHOSPHITE GROUP, AND OXIDIZING | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-6069243-A | USING ACETONITRILE HAVING WATER CONTENT BETWEEN 30 AND 1250 PPM AS WASHING AGENT BEFORE OR AFTER COUPLING OR OXIDATION STEPS OR AS OXIDIZING AGENT IN SOLID PHASE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-30 | — | — | US | disclosed |
| WO-2000027859-A1 | IMPROVED PROCESSES FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| US-6051699-A | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| WO-2000020431-A1 | IMPROVED PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| EP-0986571-A1 | NOVEL SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | HYBRIDON, INC. (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-2000014098-A1 | METHODS FOR THE PREPARATION OF CONJUGATED OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
| US-6031092-A | Preparation of phosphorothioate oligomers | MC GILL UNIVERSITY (CA) | 2000-02-29 | — | — | US | disclosed |
| US-6028183-A | Pyrimidine derivatives and oligonucleotides containing same | GILEAD SCIENCES, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| US-6020475-A | Process for the synthesis of oligomeric compounds | ISIS PHARMEUTICALS, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| WO-2000004034-A2 | OLIGONUCLEOTIDES HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
| US-6007992-A | MIXING DERIVATIVE WITH A SAMPLE CONTAINING TARGET NUCLEIC ACIDS, AND INCUBATING FORMING A COMPLEX; FOR DIAGNOSTIC ASSAYS AND TO ENHANCE BINDING TO COMPLEMENTARY BASES | GILEAD SCIENCES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-6005096-A | FOR OLIGONUCLEOTIDES THAT ARE MODIFIED TO ENHANCE THE BINDING AFFINITY AND TO BEAR DETECTABLE LABELS; FOR DIAGNOSTIC USE | GILEAD SCIENCES, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-6001982-A | Synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1999062922-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0948512-A1 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999043694-A1 | IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5945521-A | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 1999-08-31 | — | — | US | disclosed |
| WO-1999024452-A9 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 1999-08-12 | — | — | WO | disclosed |
| WO-1999024452-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| WO-1999019340-A1 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| WO-1998054198-A9 | NOVEL SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | HYBRIDON INC (US) | 1999-04-01 | — | — | WO | disclosed |
| EP-0904275-A1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | McGILL UNIVERSITY (CA) | 1999-03-31 | — | — | EP | disclosed |
| US-5866691-A | Lactam nucleic acids | ISIS PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1999003873-A2 | NOVEL SULFURIZING REAGENT 3-PHENYL-1,2,4-DITHIAZOLINE-5-ONE | HYBRIDON, INC. (US) | 1999-01-28 | — | — | WO | disclosed |
| US-5859232-A | Process for the synthesis of oligomeric phosphite, phosphodiester, phosphorothioate and phosphorodithioate compounds | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0766688-A4 | SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 1998-12-30 | — | — | EP | disclosed |
| US-5852168-A | Sulfurization of phosphorus-containing compounds | REGENTS OF THE UNIVERSITY OF MINESOTA (US) | 1998-12-22 | — | — | US | disclosed |
| US-5847106-A | Monomeric and dimeric nucleosides with silyl-containing diamino phosphorous linkages | ISIS PHARMACEUTICALS INC. (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1998054198-A1 | NOVEL SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | HYBRIDON, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998049181-A1 | NOVEL SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | HYBRIDON, INC. (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5830653-A | ABILITY TO INHIBIT GENE EXPRESSION | GILEAD SCIENCES, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| WO-1998029427-A1 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5763588-A | Pyrimidine derivatives for labeled binding partners | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5734041-A | Preparation of chiral phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 1998-03-31 | — | — | US | disclosed |
| WO-1998008809-A1 | NOVEL SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | HYBRIDON, INC. (US) | 1998-03-05 | — | — | WO | disclosed |
| US-5705621-A | Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same | ISIS PHARMACEUTICALS, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1997041130-A2 | SULFURIZATION OF PHOSPHORUS-CONTAINING COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1997-11-06 | — | — | WO | disclosed |
| US-5645985-A | USED FOR DIAGNOSIS TO DETECT VIRUSES OR DISEASED CONDITIONS | GILEAD SCIENCES, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997014710-A1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | MCGILL UNIVERSITY (US) | 1997-04-24 | — | — | WO | disclosed |
| EP-0766688-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-04-09 | — | — | EP | disclosed |
| US-5614621-A | Process for preparing oligonucleotides using silyl-containing diamino phosphorous reagents | ISIS PHARMACEUTICALS, INC. (US) | 1997-03-25 | — | — | US | disclosed |
| US-5594121-A | DETECT VIRUSES, DISEASES | GILEAD SCIENCES, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| US-5571902-A | OLIGOMERIZATION IN THE PRESENCE OF TETRAZOLE COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-05 | — | — | US | disclosed |
| US-5554746-A | Lactam nucleic acids | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0719272-A1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| US-5502177-A | POLYCYCLIC STRUCTURE BOUND TO OLIGONUCLEOTIDE, FLUORESCENT LABEL, IMMUNOASSAY | GILEAD SCIENCES, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0695306-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES | GILEAD SCIENCES, INC. (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0637965-A4 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. | GILEAD SCIENCES INC (US) | 1996-01-24 | — | — | EP | disclosed |
| WO-1995032980-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-12-07 | — | — | WO | disclosed |
| EP-0653438-A2 | Oligonucleotide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
| WO-1995007918-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0637965-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994024144-A2 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES | GILEAD SCIENCES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| WO-1993013118-A1 | SYNTHESIS OF PHOSPHOROTHIOATE ANALOGUES OF OLIGO- AND POLYNUCLEOTIDES | KING'S COLLEGE LONDON (GB) | 1993-07-08 | — | — | WO | disclosed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
| US-4399075-A | Process for producing chlorinated phenoxytoluene derivatives | ASAHI CHEMICAL COMPANY, LIMITED (JP) | 1983-08-16 | — | — | US | disclosed |
| US-4399075-A | Process for producing chlorinated phenoxytoluene derivatives | ASAHI CHEMICAL COMPANY, LIMITED (JP) | 1983-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190626-A1 | Phosphorothioate monoester modified oligomers | DCLRE1B, SNRPE, POLRMT | CES1 3375/4885CES2 4338/4885TSHR 2653/4885 |
| US-20210309690-A1 | OLIGONUCLEOTIDE SYNTHESIS | RNGTT, RTCB, TYMS | CES1 2428/4885CES2 3597/4885TSHR 2070/4885 |
| US-20020128466-A1 | Method of synthesizing phosphorothioate oligonucleotides | RNGTT, TYMP, MTAP | CES1 3379/4885CES2 4411/4885TSHR 1934/4885 |
| US-20030114662-A1 | Method of synthesizing phosphorothioate oligonucleotides | RNGTT, TYMP, MTAP | CES1 3379/4885CES2 4411/4885TSHR 1934/4885 |
| US-20070026434-A1 | Mobility-Modified Nucleobase Polymers and Methods of Using Same | PCNA, PNKP, SAMHD1 | CES1 4015/4885CES2 3182/4885TSHR 3939/4885 |
| US-20020182602-A1 | Mobility-modified nucleobase polymers and methods of using same | PCNA, PNKP, SAMHD1 | CES1 4015/4885CES2 3182/4885TSHR 3939/4885 |
| US-20120071640-A1 | Sulfurizing reagents and their use for oligonucleotides synthesis | RRM1, SRRT, NSUN2 | CES1 2337/4885CES2 3785/4885TSHR 1504/4885 |
| US-20020156235-A1 | Process for preparing peptide derivatized oligomeric compounds | IAPP, PTMS, NGLY1 | CES1 4792/4885CES2 4881/4885TSHR 3062/4885 |
| US-20090286085-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | NEFM, NOD2, MACF1 | CES1 4712/4885CES2 4601/4885TSHR 4838/4885 |
| US-20050137391-A1 | Process for the synthesis of oligomeric compounds | PFAS, DIS3, EXOSC4 | CES1 3984/4885CES2 2639/4885TSHR 3941/4885 |
| US-20060036028-A1 | Process for preparing oligonucleotides | RTCB, POLRMT, POLM | CES1 2004/4885CES2 3168/4885TSHR 3722/4885 |
| US-20030208061-A1 | Labeled oligonucleotides, methods for making same, and compounds useful therefor | METTL16, BCDIN3D, GARS1 | CES1 1444/4885CES2 1668/4885TSHR 3410/4885 |
| US-20040185491-A1 | Methods for synthesis of oligonucleotides | RNGTT, POLL, TYMP | CES1 3140/4885CES2 2529/4885TSHR 970/4885 |
| US-20040063925-A1 | Synthesis of oligonucleotides | RNGTT, POLRMT, POLI | CES1 3229/4885CES2 4046/4885TSHR 2331/4885 |
| US-20100069623-A1 | Method for preparing oligonucleotides | RNGTT, NSUN2, RNMT | CES1 2452/4885CES2 2762/4885TSHR 2547/4885 |
| US-11608355-B2 | Technologies for oligonucleotide preparation | POLRMT, DCLRE1B, RNGTT | CES1 2271/4885CES2 4249/4885TSHR 2860/4885 |
| US-20010003132-A1 | Method of synthesizing phosphorothioate oligonucleotides | RNGTT, TYMP, MTAP | CES1 3379/4885CES2 4411/4885TSHR 1934/4885 |
| US-20030072712-A1 | Pyrimidine derivatives for labeled binding partners | DDB1, RRBP1, PRPF31 | CES1 2896/4885CES2 3970/4885TSHR 2809/4885 |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, SNRPB2, RNGTT | CES1 4258/4885CES2 3112/4885TSHR 1669/4885 |
| US-20020010326-A1 | NOVEL SULFURIZING REAGENT 3-PHENYL-1,2,4-DITHIAZOLINE-5-ONE | BPNT1, DNTT, TST | CES1 3159/4885CES2 3454/4885TSHR 3174/4885 |
| US-20030170680-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | CES1 3840/4885CES2 4627/4885TSHR 3775/4885 |
| US-20110196145-A1 | PROCESS FOR DESILYLATION OF OLIGONUCLEOTIDES | ALKBH1, DIMT1, RNGTT | CES1 1507/4885CES2 964/4885TSHR 3087/4885 |
| US-20060040308-A1 | Compounds and methods for the characterization of oligonucleotides | POLRMT, DCLRE1B, RNGTT | CES1 1142/4885CES2 1054/4885TSHR 2682/4885 |
| US-20260008806-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | RNGTT, RNMT, NSUN2 | CES1 1538/4885CES2 1633/4885TSHR 1346/4885 |
| US-20030229220-A1 | Oligomer phosphoramidite compositions and processes for synthesizing the same | PHOSPHO1, OSGEP, DTYMK | CES1 4262/4885CES2 4548/4885TSHR 3963/4885 |
| US-20230002438-A1 | COMPOSITIONS COMPRISING DICHLOROACETIC ACID, PROCESSES FOR PREPARING SAME AND USES THEREOF | AGXT, DDC, GRHPR | CES1 921/4885CES2 516/4885TSHR 4683/4885 |
| US-20090306358-A1 | SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | POLRMT, TST, DNTT | CES1 3968/4885CES2 3824/4885TSHR 2699/4885 |
| US-20060051800-A1 | Polymeric beads for oligomer synthesis | NEFM, NOD2, MACF1 | CES1 4712/4885CES2 4601/4885TSHR 4838/4885 |
| US-20100137572-A1 | OXIDATION PROCESS | POLRMT, POLN, POLB | CES1 4341/4885CES2 4333/4885TSHR 1981/4885 |
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | CES1 4288/4885CES2 2416/4885TSHR 4585/4885 |
| US-20080097028-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | NEFM, NOD2, MACF1 | CES1 4712/4885CES2 4601/4885TSHR 4838/4885 |
| US-20040198972-A1 | Processes for the preparation of oligonucleotides | RNGTT, RNMT, NUDT1 | CES1 3662/4885CES2 3982/4885TSHR 3203/4885 |
| US-20030088088-A1 | Process for the synthesis of oligomeric compounds | PFAS, DIS3, EXOSC4 | CES1 3984/4885CES2 2639/4885TSHR 3941/4885 |
| US-20060041114-A1 | Activators for oligonucleotide synthesis | MED12, RBM12, RPS12 | CES1 1315/4885CES2 2838/4885TSHR 1293/4885 |
| US-20050182251-A1 | Process for the synthesis of oligomeric compounds | PFAS, DIS3, EXOSC4 | CES1 3984/4885CES2 2639/4885TSHR 3941/4885 |
| US-12435105-B2 | Technologies for oligonucleotide preparation | POLRMT, DCLRE1B, RNGTT | CES1 2271/4885CES2 4249/4885TSHR 2860/4885 |
| US-20050075490-A1 | Chloral-free DCA in oligonucleotide synthesis | DCLRE1B, DCTD, DDT | CES1 422/4885CES2 235/4885TSHR 678/4885 |
| US-20070265435-A1 | PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS | PFAS, DIS3, EXOSC4 | CES1 3984/4885CES2 2639/4885TSHR 3941/4885 |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | NUDT1, DHX15, DDX5 | CES1 3840/4885CES2 4627/4885TSHR 3775/4885 |
| US-20090005549-A1 | Processes and Reagents for Desilylation of Oligonucleotides | ALKBH1, DIMT1, RNGTT | CES1 1520/4885CES2 990/4885TSHR 2468/4885 |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | CES1 4288/4885CES2 2416/4885TSHR 4585/4885 |
| US-20010016652-A1 | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds | PPIP5K2, NUDT1, ITPA | CES1 4236/4885CES2 3951/4885TSHR 4500/4885 |
| US-20030153743-A1 | Processes for the synthesis of oligomeric compounds | PPIP5K2, NUDT21, NUDT1 | CES1 4073/4885CES2 4735/4885TSHR 3095/4885 |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | CES1 4288/4885CES2 2416/4885TSHR 4585/4885 |
| US-20030229218-A1 | Synthons for oligonucleotide synthesis | POLI, TYMP, POLRMT | CES1 2738/4885CES2 4053/4885TSHR 1349/4885 |
| US-20040219577-A1 | Process for the synthesis of oligomeric compounds | PFAS, DIS3, EXOSC4 | CES1 3984/4885CES2 2639/4885TSHR 3941/4885 |
| US-20060149052-A1 | Process for the preparation of oligonucleotides | CPSF7, CPSF1, CPSF6 | CES1 3456/4885CES2 3594/4885TSHR 2641/4885 |
| US-20040152905-A1 | Universal building blocks and support media for synthesis of oligonucleotides and their analogs | POLM, POLRMT, POLB | CES1 3785/4885CES2 4432/4885TSHR 3397/4885 |
| US-20150240053-A1 | POLYSULFIDE ADDITIVE, METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN RUBBER MIXTURES | PUF60, RPS21, RPS4Y1 | CES1 3782/4885CES2 2001/4885TSHR 4724/4885 |
| US-20030176677-A1 | Pyrimidine derivatives for labeled binding partners | DDB1, RRBP1, PRPF31 | CES1 2896/4885CES2 3970/4885TSHR 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.